Supriya Lifescience Limited Stock Price Today (NSE: SUPRIYA)
Fundamental Score
Supriya Lifescience Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Supriya Lifescience Limited share price today is ₹877.85, up +0.33% on NSE/BSE as of 16 September 2026. Supriya Lifescience Limited (SUPRIYA) is a Mid-cap company in the Pharmaceuticals sector with a market capitalisation of ₹7.07K (Cr). The 52-week high for SUPRIYA share price is ₹1085.00 and the 52-week low is ₹545.50. At a P/E ratio of 35.61x, SUPRIYA is currently trading above its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 19.06% and a debt-to-equity ratio of 0.00.
Supriya Lifescience Limited Share Price Chart — NSE/BSE Historical Performance
Supriya Lifescience Limited share price chart: -1.24% return over the past month. 52-week high ₹1085.00, 52-week low ₹545.50.
Supriya Lifescience Limited — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹863.75 | ₹889.45 | ₹845.55 | ₹877.85 | 1.92L (Cr) | |
| ₹904.50 | ₹912.75 | ₹866.25 | ₹874.95 | 1.66L (Cr) | |
| ₹915.00 | ₹915.30 | ₹891.25 | ₹901.75 | 2.09L (Cr) | |
| ₹912.00 | ₹933.15 | ₹902.80 | ₹917.45 | 2.44L (Cr) | |
| ₹911.30 | ₹925.00 | ₹899.10 | ₹911.40 | 1.96L (Cr) | |
| ₹910.00 | ₹925.10 | ₹898.50 | ₹915.65 | 2.66L (Cr) | |
| ₹869.90 | ₹923.00 | ₹864.00 | ₹909.10 | 12.26L (Cr) | |
| ₹838.55 | ₹868.00 | ₹838.55 | ₹852.85 | 3.24L (Cr) | |
| ₹850.00 | ₹852.90 | ₹834.00 | ₹842.70 | 1.96L (Cr) | |
| ₹803.00 | ₹849.50 | ₹800.00 | ₹841.20 | 9.61L (Cr) |
Supriya Lifescience Limited — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹798.30 | ₹933.15 | ₹795.50 | ₹877.85 | +9.96% | |
| ₹867.05 | ₹951.00 | ₹740.45 | ₹798.30 | -7.93% | |
| ₹1025.00 | ₹1038.60 | ₹816.10 | ₹867.00 | -15.41% | |
| ₹990.00 | ₹1085.00 | ₹880.00 | ₹1018.05 | +2.83% | |
| ₹694.90 | ₹968.70 | ₹666.00 | ₹968.70 | +39.40% | |
| ₹569.95 | ₹717.45 | ₹569.95 | ₹694.90 | +21.92% | |
| ₹620.70 | ₹649.00 | ₹545.50 | ₹561.90 | -9.47% | |
| ₹670.20 | ₹721.00 | ₹649.95 | ₹655.00 | -2.27% | |
| ₹753.00 | ₹775.00 | ₹658.00 | ₹676.05 | -10.22% | |
| ₹751.15 | ₹762.80 | ₹706.85 | ₹751.50 | +0.05% | |
| ₹778.00 | ₹832.40 | ₹724.75 | ₹747.50 | -3.92% | |
| ₹729.90 | ₹799.80 | ₹680.70 | ₹776.90 | +6.44% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Supriya Lifescience Limited Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Supriya Lifescience Limited Fundamental Analysis & Valuation Benchmarking
Educational evaluation of SUPRIYA across key market metrics for learning purposes.
Positive Indicators
10 factors identified
Strong Return on Equity (19.06%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (24.42%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (35.58%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Strong Revenue Growth (30.79%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Consistent Growth Track Record (16.17% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Debt-Free Balance Sheet (D/E: 0.00)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (146.46x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Healthy Liquidity Position (Current Ratio: 5.32)
Observation: Strong short-term liquidity to meet obligations.
Analysis: Current ratio >1.5 indicates good working capital management.
Balanced Promoter Holding (68.30%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
3 factors identified
High Price-to-Book Ratio (7.09x)
Observation: Trading at significant premium to book value.
Analysis: High P/B ratios may indicate overvaluation relative to asset base.
Profit Decline Concern (-30.89%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Negative Free Cash Flow (₹-51.92 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Supriya Lifescience Limited vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Supriya Lifescience Limited with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Supriya Lifescience LimitedSupriya Lifesci...Selected✓ SUPRIYA • 543434 | 68.5/100 | ₹877.85₹878 | ₹7065.38₹7065.38 | 35.61Average 35.6 Average | 19.06%Good 19.06% Good | 24.42%Excellent 24.42% Excellent | 0.00Excellent 0.0 Excellent | 11.13%Good 11.13% Good | 16.17%Excellent 16.17% Excellent | 0.12% |
Sun Pharmaceutical Industries LimitedSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1864.90₹1865 | ₹447445.46₹447445.46 | 37.00Average 37.0 Average | 14.74%Average 14.74% Average | 19.31%Good 19.31% Good | 0.05Excellent 0.0 Excellent | 31.64%Excellent 31.64% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divi's Laboratories LimitedDivi's Laborato... DIVISLAB • 532488 | 56.3/100 | ₹9488.00₹9488 | ₹251432.00₹251432.00 | 86.09Average 86.1 Average | 16.19%Good 16.19% Good | 20.38%Excellent 20.38% Excellent | 0.00Excellent 0.0 Excellent | 5.29%Good 5.29% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LimitedTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹4930.00₹4930 | ₹166860.78₹166860.78 | 78.75Average 78.8 Average | 27.07%Excellent 27.07% Excellent | 14.09%Average 14.09% Average | 1.76Average 1.8 Average | 11.56%Good 11.56% Good | 11.80%Good 11.80% Good | 0.76% |
Zydus Lifesciences LimitedZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1127.40₹1127 | ₹112514.52₹112514.52 | 25.13Average 25.1 Average | 19.74%Good 19.74% Good | 21.77%Excellent 21.77% Excellent | 0.43Excellent 0.4 Excellent | 18.76%Excellent 18.76% Excellent | 12.45%Good 12.45% Good | 0.09% |
Cipla LimitedCipla Limited... CIPLA • 500087 | 40.2/100 | ₹1363.10₹1363 | ₹110118.03₹110118.03 | 32.66Average 32.7 Average | 11.82%Average 11.82% Average | 15.67%Good 15.67% Good | 0.01Excellent 0.0 Excellent | 10.03%Good 10.03% Good | 8.01%Good 8.01% Good | 0.90% |
Laurus Labs LimitedLaurus Labs Lim... LAURUSLABS • 540222 | 34.1/100 | ₹1937.00₹1937 | ₹104646.43₹104646.43 | 95.61Average 95.6 Average | 18.19%Good 18.19% Good | 21.35%Excellent 21.35% Excellent | 0.45Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Aurobindo Pharma LimitedAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1698.90₹1699 | ₹97754.71₹97754.71 | 26.55Average 26.5 Average | 9.94%Poor 9.94% Poor | 14.54%Average 14.54% Average | 0.20Excellent 0.2 Excellent | -8.07%Poor -8.07% Poor | 6.32%Good 6.32% Good | 0.26% |
Lupin LimitedLupin Limited... LUPIN • 500257 | 83.4/100 | ₹2100.00₹2100 | ₹96022.50₹96022.50 | 17.35Average 17.4 Average | 26.90%Excellent 26.90% Excellent | 31.80%Excellent 31.80% Excellent | 0.26Excellent 0.3 Excellent | 34.39%Excellent 34.39% Excellent | 13.02%Good 13.02% Good | 0.72% |
Dr. Reddy's Laboratories LimitedDr. Reddy's Lab... DRREDDY • 500124 | 41/100 | ₹1145.00₹1145 | ₹95607.50₹95607.50 | 29.59Average 29.6 Average | 11.75%Average 11.75% Average | 14.80%Average 14.80% Average | 0.17Excellent 0.2 Excellent | 16.54%Excellent 16.54% Excellent | 12.09%Good 12.09% Good | 0.65% |
Mankind Pharma LimitedMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2265.00₹2265 | ₹93544.50₹93544.50 | 45.77Average 45.8 Average | 12.49%Average 12.49% Average | 13.56%Average 13.56% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Limited share price447445.46 Cr
- Divi's Laboratories Limited share price251432.00 Cr
- Torrent Pharmaceuticals Limited share price166860.78 Cr
- Zydus Lifesciences Limited share price112514.52 Cr
- Cipla Limited share price110118.03 Cr
Supriya Lifescience Limited PE Ratio History
Historical price-to-earnings ratio for SUPRIYA — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹23.35 | ₹751.50 | 32.2x |
| FY 2024 | ₹14.80 | ₹739.80 | 50x |
| FY 2023 | ₹11.16 | ₹314.75 | 28.2x |
| FY 2022 | ₹18.86 | ₹235.05 | 12.5x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Supriya Lifescience Limited Dividend History
Annual cash dividends paid by SUPRIYA — dividend yield 0.12%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2025 | ₹6.44 Cr |
| FY 2024 | ₹4.83 Cr |
| FY 2023 | ₹4.83 Cr |
| FY 2022 | ₹4.39 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Supriya Lifescience Limited Quarterly Performance
Latest quarterly metrics for SUPRIYA — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
30.79%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
-30.89%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
16.17%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
11.13%
Compounded annual net profit growth over 5 years
Supriya Lifescience Limited Technical Indicators
SMA 50, SMA 200, RSI and volume signals for SUPRIYA — calculated from daily price history
Momentum is strong — price may be stretched. Watch for pullbacks.
Technical indicators are for educational purposes only. Not investment advice.
Supriya Lifescience Limited Financial Statements
Annual income statement, balance sheet and cash flow for Supriya Lifescience Limited (SUPRIYA) — sourced from NSE/BSE filings.
Financial Results & Statements
Latest quarterly, annual and period-wise financial data for Supriya Lifescience Limited
About SUPRIYA (Supriya Lifescience Limited)
Supriya Lifescience Ltd is a dynamic pharmaceutical company focused on developing, manufacturing, and distributing high-quality active pharmaceutical ingredients (APIs) and special...ty chemicals across the globe. With a strong emphasis on innovation and customer satisfaction, Supriya strives to be a reliable partner to pharmaceutical companies worldwide, offering a diverse portfolio of products targeting a broad spectrum of therapeutic areas. The company leverages advanced manufacturing processes and a dedicated research and development team to ensure product excellence and meet the stringent regulatory requirements of the global pharmaceutical market. Supriya Lifescience is committed to advancing healthcare by providing essential building blocks for life-saving medications. The company’s comprehensive API range covers critical therapeutic segments including treatments for respiratory ailments such as antihistamines and anti-asthmatics, pain management solutions comprising analgesics and anesthetics, cardiovascular health with anti-hypertensives, and essential vitamins. Supriya also provides APIs for oncology, veterinary medicine, and general healthcare, demonstrating its wide-ranging capabilities and commitment to addressing diverse medical needs. Furthermore, the company continues to expand its product line through strategic collaborations and in-house research, solidifying its position as a versatile and adaptive player in the pharmaceutical landscape. Beyond APIs, Supriya Lifescience demonstrates its commitment to innovative healthcare solutions through the development of specialized products like GelHeal, an advanced wound care solution. This showcases the company’s dedication to addressing specific patient needs with cutting-edge technology. Driven by a customer-centric approach and a commitment to ethical practices, Supriya Lifescience Ltd aims to consistently deliver high-quality products, reliable service, and sustainable growth, contributing significantly to the advancement of global healthcare.
Company Details
Key Leadership
SUPRIYA Share Price: Frequently Asked Questions
What is the current share price of Supriya Lifescience Limited?
Supriya Lifescience Limited (SUPRIYA) trades at ₹877.85 on NSE and BSE. Market cap ₹7.07K (Cr). Educational data only.
What is the P/E ratio of Supriya Lifescience Limited?
Supriya Lifescience Limited has a P/E of 35.61x vs industry average 34.89x.
What is the Bull Run score for Supriya Lifescience Limited?
Supriya Lifescience Limited has a Bull Run score of 68.5/100 based on 25+ financial parameters.
Does Supriya Lifescience Limited pay dividends?
Supriya Lifescience Limited has a dividend yield of 0.12%. Past dividends don't guarantee future payments.
What is the ROE of Supriya Lifescience Limited?
Supriya Lifescience Limited has ROE of 19.06%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Supriya Lifescience Limited?
Supriya Lifescience Limited has debt-to-equity of 0.00.
Is Supriya Lifescience Limited a good investment?
Bull Run gives Supriya Lifescience Limited a score of 68.5/100. This is not investment advice — consult a SEBI-registered advisor.